Not Yet RecruitingPhase 2ACTRN12607000384459

To evaluate the efficacy of nasal oxytocin in the treatment of migraine headaches

A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate Nasal Oxytocin for the Treatment of Migraine Headaches


Sponsor

Trigemina, Inc

Enrollment

100 participants

Start Date

Sep 1, 2007

Study Type

Interventional

Conditions

Summary

Nasal oxytocin may be useful in preventing migraine attacks. The purpose of this study is to determine how well nasal oxytocin helps treat migraine attacks and the safety of nasal oxytocin and any side effects that may happen when it is given to migraine patients


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 65 Yearss

Inclusion Criteria1

  • Diagnosed with migraine according to IHS-criteria (see Appendix 1)Suffering from migraine > 1 yearAt least 1-6 attacks per month in each of the six months prior to the start of this study Typical migraines of at least moderate intensity (based on a 5 point scale) if left untreatedAbility to reliably identify the onset of a migraine attackStarted suffering from migraine before age 50 years Female subjects of child-bearing potential who are fewer than 2 years post-menopausal, must agree to, and comply with, using highly effective methods of birth control (i.e. condom plus spermicide, combined oral contraceptive, implant, injectable, indwelling intrauterine device, sexual abstinence, or a vasectomized partner) while participating in this study.Written informed consent, willingness, and ability to comply with all study procedures

Exclusion Criteria1

  • Currently taking another investigational drug.Allergic to certain additives in the nasal oxytocin medication.Have other medical conditions that may interfere with participation in this study.Female and are pregnant or are nursing and will not agree to stop nursing.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

active drug: nasal oxytocin administered as one puff (100µL, 4IU) in each nostril at time 0, 5 minutes, 10 minutes and 15 minutes on Study Day 1

active drug: nasal oxytocin administered as one puff (100µL, 4IU) in each nostril at time 0, 5 minutes, 10 minutes and 15 minutes on Study Day 1


View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000384459


Related Trials